ERBB2 and non-small cell lung carcinoma: Importantly, the DESTINY-Lung01 study included a cohort of HER2-mutant NSCLC patients with stable BM, comprising 33 of the 91 (36.3%) patients included in the study (Figure 2) (Table 1).